In life sciences, the real innovation isn’t always the tech.
It’s the clarity of the story around it.
#founderstorytelling
#biotechstrategy
#scicomm
It’s the clarity of the story around it.
#founderstorytelling
#biotechstrategy
#scicomm
July 7, 2025 at 4:03 PM
In life sciences, the real innovation isn’t always the tech.
It’s the clarity of the story around it.
#founderstorytelling
#biotechstrategy
#scicomm
It’s the clarity of the story around it.
#founderstorytelling
#biotechstrategy
#scicomm
Are you a biopharma C-suite exec or investor dissecting rare disease playbooks?
Then this one's for you.
www.linkedin.com/posts/mattkr...
Then this one's for you.
www.linkedin.com/posts/mattkr...
#raredisease #biotechstrategy #biomarin | Matt Krebs
Are you a biopharma C-suite exec or investor dissecting rare disease playbooks?
Then this one's for you.
BioMarin Pharmaceutical Inc. just made its 1st acquisition in 10+ yrs.
The $270M price ...
www.linkedin.com
May 19, 2025 at 2:07 PM
Are you a biopharma C-suite exec or investor dissecting rare disease playbooks?
Then this one's for you.
www.linkedin.com/posts/mattkr...
Then this one's for you.
www.linkedin.com/posts/mattkr...
Attending the Society for Immunotherapy of Cancer (SITC) NYSE 2025 Biotech Strategic Meeting? Don't miss this panel! Register at buff.ly/wVt2kLk
#ImmunoTherapy #BiotechStrategy #SITCNYSE2025 #SITC #NYSE #BiotechInnovation #ImmunoOncology #Cancer #Oncology
#ImmunoTherapy #BiotechStrategy #SITCNYSE2025 #SITC #NYSE #BiotechInnovation #ImmunoOncology #Cancer #Oncology
June 12, 2025 at 1:52 PM
Attending the Society for Immunotherapy of Cancer (SITC) NYSE 2025 Biotech Strategic Meeting? Don't miss this panel! Register at buff.ly/wVt2kLk
#ImmunoTherapy #BiotechStrategy #SITCNYSE2025 #SITC #NYSE #BiotechInnovation #ImmunoOncology #Cancer #Oncology
#ImmunoTherapy #BiotechStrategy #SITCNYSE2025 #SITC #NYSE #BiotechInnovation #ImmunoOncology #Cancer #Oncology
Communicate your science the way the brain remembers it.
Stories activate multiple brain regions simultaneously, giving context and emotional weight to data. Investors retain narratives of discovery far more than raw numbers.
Read here:
www.zeeks-artforgeeks.com/post/032-the...
#BiotechStrategy
Stories activate multiple brain regions simultaneously, giving context and emotional weight to data. Investors retain narratives of discovery far more than raw numbers.
Read here:
www.zeeks-artforgeeks.com/post/032-the...
#BiotechStrategy
www.zeeks-artforgeeks.com
April 2, 2026 at 12:56 PM
Communicate your science the way the brain remembers it.
Stories activate multiple brain regions simultaneously, giving context and emotional weight to data. Investors retain narratives of discovery far more than raw numbers.
Read here:
www.zeeks-artforgeeks.com/post/032-the...
#BiotechStrategy
Stories activate multiple brain regions simultaneously, giving context and emotional weight to data. Investors retain narratives of discovery far more than raw numbers.
Read here:
www.zeeks-artforgeeks.com/post/032-the...
#BiotechStrategy
Raw data rarely convinces investors.
After three years running Zeeks and working closely with biotech founders, I can say with confidence: clarity and relevance are what shift a conversation from interest to investment.
www.zeeks-artforgeeks.com/post/031-how...
1/4
#BiotechStrategy #DataToDecision
After three years running Zeeks and working closely with biotech founders, I can say with confidence: clarity and relevance are what shift a conversation from interest to investment.
www.zeeks-artforgeeks.com/post/031-how...
1/4
#BiotechStrategy #DataToDecision
www.zeeks-artforgeeks.com
February 27, 2026 at 2:02 PM
Raw data rarely convinces investors.
After three years running Zeeks and working closely with biotech founders, I can say with confidence: clarity and relevance are what shift a conversation from interest to investment.
www.zeeks-artforgeeks.com/post/031-how...
1/4
#BiotechStrategy #DataToDecision
After three years running Zeeks and working closely with biotech founders, I can say with confidence: clarity and relevance are what shift a conversation from interest to investment.
www.zeeks-artforgeeks.com/post/031-how...
1/4
#BiotechStrategy #DataToDecision
#BiotechLeadership #LifeSciences #Biotechnology #Biopharma #ExecutiveSearch #HealthcareInvestors #MedTech #TechBio #DrugDevelopment #BiotechStrategy #ClinicalTrials #AIinBiotech #FutureOfBiotech #BiotechFunding #LifeSciences
www.youtube.com/shorts/9fj65...
www.dailymail.co.uk/news/article...
www.youtube.com/shorts/9fj65...
www.dailymail.co.uk/news/article...
www.dailymail.co.uk
April 15, 2026 at 1:08 AM
BioNTech's Dilemma: Covid Boosters or Diversification? 🤔
Explore this product strategy challenge with NextSprints. Learn to balance market demands and long-term growth.
#ProductManagement #BiotechStrategy
Explore this product strategy challenge with NextSprints. Learn to balance market demands and long-term growth.
#ProductManagement #BiotechStrategy
May 6, 2025 at 7:15 PM
BioNTech's Dilemma: Covid Boosters or Diversification? 🤔
Explore this product strategy challenge with NextSprints. Learn to balance market demands and long-term growth.
#ProductManagement #BiotechStrategy
Explore this product strategy challenge with NextSprints. Learn to balance market demands and long-term growth.
#ProductManagement #BiotechStrategy